CV Sciences Restructures Debt with Highly Dilutive Convertible Notes and Open-Ended True-Up Provision
CVSI sits 98% above its 52-week low of $0.023 on elevated volume (4.1× avg).
Summary
CV Sciences, a micro-cap company, has restructured its existing secured promissory notes, converting them into highly dilutive convertible notes with a fixed conversion price of $0.06 per share and an open-ended true-up provision.
Key Events · Financing and Capital Events · CVSI
-
Debt Restructuring Agreement
CV Sciences amended existing secured promissory notes totaling $2.256 million with an institutional investor on March 4, 2026.
-
New Convertible Feature
The notes are now convertible into common stock at a fixed price of $0.06 per share, initially convertible into 37.6 million shares.
-
Significant Potential Dilution
The company has reserved 112.8 million shares for potential conversion, indicating a substantial increase in outstanding shares and over 60% potential dilution.
-
Open-Ended True-Up Provision
A clause allows for the issuance of additional convertible notes if the investor's net proceeds from selling converted shares fall short of the principal, with no maximum limit on future share issuance, creating significant dilution risk.
Analysis · CVSI · Life Sciences
This 8-K details a critical debt restructuring for CV Sciences, a micro-cap company. Existing secured promissory notes totaling $2.256 million have been amended to include a conversion feature into common stock at a fixed price of $0.06 per share. While this conversion price is above the current stock price of $0.0456, the terms are significantly dilutive for existing shareholders. The notes are initially convertible into 37.6 million shares, representing a substantial portion of the company's current market capitalization. Furthermore, the company has reserved 112.8 million shares for potential conversion, indicating a potential dilution of over 60%. The most concerning aspect is the 'true-up' provision, which allows for the issuance of additional notes (and thus more shares) if the investor's net proceeds from selling converted shares fall short of the principal amount, with no stated maximum. This creates an open-ended dilution risk, often associated with 'death spiral' financing, and signals the company's distressed financial position despite the immediate relief from eliminating monthly redemption obligations. Investors should be aware of the severe long-term dilution potential.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42.4% of the 495 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVSI was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.02 to $0.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.